Top Page
Indivior
(NASDAQ:INDV)
Indivior (INDV) vs. SPDR S&P 500 ETF (SPY)
Indivior Business Overview & Revenue Model
Indivior Earnings Call Summary
Indivior Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18B | 1.19B | 1.09B | 901.00M | 791.00M | 647.00M |
| Gross Profit | 978.00M | 957.00M | 919.00M | 750.00M | 664.00M | 550.00M |
| EBITDA | 315.00M | 84.00M | -99.00M | -46.00M | 238.00M | -123.00M |
| Net Income | 166.00M | 2.00M | -129.00M | -44.00M | 205.00M | -148.00M |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B |
| Cash, Cash Equivalents and Short-Term Investments | 445.00M | 320.00M | 410.00M | 897.83M | 1.10B | 858.00M |
| Total Debt | 356.00M | 375.00M | 283.00M | 277.00M | 286.00M | 285.00M |
| Total Liabilities | 1.62B | 1.67B | 1.96B | 1.73B | 1.63B | 1.45B |
| Stockholders Equity | -207.00M | -348.00M | -191.00M | 51.28M | 203.00M | 82.00M |
Cash Flow | ||||||
| Free Cash Flow | 137.89M | 7.00M | -353.00M | -9.00M | 319.00M | -197.00M |
| Operating Cash Flow | 196.40M | 36.00M | -300.00M | -4.00M | 353.00M | -193.00M |
| Investing Cash Flow | -34.57M | 69.00M | -95.00M | -222.00M | -14.00M | -4.00M |
| Financing Cash Flow | 4.44M | -102.00M | -64.00M | -101.00M | -94.00M | -10.00M |
Indivior Technical Analysis
Indivior Risk Analysis
Indivior Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $13.14B | 28.10 | 16.38% | ― | 19.61% | 11.36% | |
64 Neutral | $4.61B | 1,026.76 | ― | ― | 9.50% | ― | |
63 Neutral | $39.96B | 27.62 | 21.37% | ― | -0.25% | ― | |
62 Neutral | $4.13B | 33.48 | ― | ― | -0.25% | ― | |
62 Neutral | $1.43B | 28.47 | 22.96% | ― | 26.34% | -32.79% | |
55 Neutral | $3.06B | -82.35 | -1.86% | ― | 4.54% | -130.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Indivior Corporate Events
On January 26, 2026, Indivior U.S. announced the effectiveness of a court-approved Scheme of Arrangement and the completion of its U.S. Domestication, under which Indivior Pharmaceuticals, Inc. became the ultimate parent of Indivior U.K., each Indivior U.K. ordinary share was exchanged for Indivior U.S. common stock, and the company’s financial reporting and capital structure shifted from the U.K. to a Delaware, U.S.-listed framework. In connection with the change of domicile, the company amended its existing Note Purchase Agreement so that financial statements and related covenants are now reported at the U.S. top company level, put in place broad indemnification agreements for directors and executive officers, replicated the prior U.K. board and committee structure under Indivior U.S., assumed and updated legacy equity incentive and savings plans while adopting a new 2026 Omnibus Equity Incentive Plan and a detailed non-employee director compensation policy, and implemented a Delaware-style charter and bylaws featuring anti-takeover protections, director election mechanics, and forum-selection and indemnification provisions that collectively strengthen its U.S. corporate governance framework and may influence control contests and stockholder litigation dynamics.
The most recent analyst rating on (INDV) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On January 8, 2026, Indivior issued full-year 2026 financial guidance, projecting total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected at $905 million to $945 million, non-GAAP operating expenses of $430 million to $450 million, and adjusted EBITDA of $535 million to $575 million, implying strong margin expansion driven by growth in SUBLOCADE dispense units and a simplified operating model. The company reported completing Phase I of its Indivior Action Agenda in 2025—generating momentum by growing U.S. SUBLOCADE revenue, simplifying the organization and transforming its operating model to deliver at least $150 million in annual non-GAAP operating expense savings—and said it entered Phase II, “Accelerate,” on January 1, 2026, while also highlighting its December 22, 2025 inclusion in the S&P SmallCap 600 index, shareholder approval to redomicile from the U.K. to the U.S. with the new parent Indivior Pharmaceuticals, Inc. expected on January 26, 2026, and the full settlement of a legacy U.S. Department of Justice obligation of $295 million, collectively reinforcing its financial flexibility, U.S. market focus and standing with investors and regulators.
The most recent analyst rating on (INDV) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On December 22, 2025, Indivior PLC announced that its ordinary shares were included in the S&P SmallCap 600 index, aligning its capital markets profile more closely with its U.S.-focused business and signaling that it meets key criteria for liquidity and financial viability in the small-cap segment. Management highlighted the move as a significant milestone that supports its strategy to grow SUBLOCADE, its leading long-acting injectable treatment for moderate to severe opioid use disorder, under a simplified operating model, which could enhance visibility among investors and potentially bolster its competitive position in the addiction-treatment market.
The most recent analyst rating on (INDV) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On December 12, 2025, Indivior PLC’s board approved base salary increases for its top executives, effective January 1, 2026, following a competitive market review and recommendations from its Compensation Committee and external consultants. Chief Executive Officer Joseph Ciaffoni’s annual base salary will rise from $1,050,000 to $1,115,000, while Chief Financial Officer Ryan Preblick’s base pay will increase from $559,000 to $604,000, signaling the company’s intention to retain and reward senior leadership amid ongoing market pressures in the pharmaceutical sector.
The most recent analyst rating on (INDV) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On December 11, 2025, Indivior PLC shareholders approved amended articles of association to facilitate a scheme of arrangement. This scheme ensures that Indivior PLC becomes a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. The approval process included two shareholder meetings, with resolutions passed to authorize necessary actions for the scheme’s implementation. The scheme’s completion is pending a court sanction expected in January 2026.
The most recent analyst rating on (INDV) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On November 20, 2025, Indivior PLC announced the conclusion of its legacy matter with the U.S. Department of Justice by paying the remaining $295 million obligation. This payment, funded from the company’s cash reserves, terminates the resolution agreement with the DOJ, removing a significant liability and simplifying Indivior’s capital structure.
The most recent analyst rating on (INDV) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
On November 14, 2025, Indivior PLC announced its plan to re-domicile from the U.K. to Delaware, a move that will be voted on by shareholders at an Extraordinary General Meeting on December 11, 2025. This strategic shift is aimed at establishing Indivior Pharmaceuticals, Inc. as the new holding company for the Indivior Group, potentially impacting its operational framework and market positioning.
The most recent analyst rating on (INDV) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Indivior reported its third-quarter 2025 financial results, showing a 2% year-over-year increase in total net revenue to $314 million, driven by a 15% rise in SUBLOCADE’s net revenue. The company has raised its full-year 2025 financial guidance, expecting significant growth in adjusted EBITDA. Indivior is optimizing its Rest of World business by exiting several non-U.S. markets and plans to redomicile in the U.S. These strategic moves are expected to generate substantial operating expense savings and improve cash generation starting in 2026.
The most recent analyst rating on (INDV) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.